Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

$24.99

Common-Size Income Statement

Amgen Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Product sales
Cost of sales
Gross profit from product sales
Other revenues
Research and development
Acquired in-process research and development
Selling, general and administrative
Other
Operating income
Interest expense, net
Other income (expense), net
Income before income taxes
Provision for income taxes
Net income

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Amgen Inc. operating income as a percentage of product sales decreased from 2022 to 2023 and from 2023 to 2024.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Amgen Inc. income before income taxes as a percentage of product sales decreased from 2022 to 2023 and from 2023 to 2024.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Amgen Inc. net income as a percentage of product sales decreased from 2022 to 2023 and from 2023 to 2024.